Risk factors of cytomegalovirus infection after pediatric liver transplantation and effectiveness of preemptive therapy.
cytomegalovirus infection
liver transplantation
pediatric
preemptive therapy
Journal
Transplant infectious disease : an official journal of the Transplantation Society
ISSN: 1399-3062
Titre abrégé: Transpl Infect Dis
Pays: Denmark
ID NLM: 100883688
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
23
02
2023
received:
02
11
2022
accepted:
09
03
2023
medline:
19
6
2023
pubmed:
5
4
2023
entrez:
4
4
2023
Statut:
ppublish
Résumé
Cytomegalovirus (CMV) infection is the most common infection following pediatric liver transplantation (LT). Preemptive therapy (PET) is an approach to initiate antiviral treatment for asymptomatic early CMV viremia detected by surveillance testing. However, data on CMV infection after PET are scarce, and the optimal cut-off remains controversial. This study aimed to evaluate the incidence, risk factors, and consequences of CMV infection in pediatric LT using 2 different viral load (VL) cut-offs. We retrospectively reviewed patients aged 0-18 years who underwent LT at Ramathibodi Hospital between March 2001 and August 2020. Demographic data, CMV infection, CMV treatment, and consequences of CMV infection were collected. CMV viremia was monitored by a quantitative nucleic acid amplification test. Clinical outcomes were compared after starting antiviral therapy at a low (>400 but <2000 IU/mL) and a high VL cut-off (≥2000 IU/mL). A total of 126 patients were included. CMV infection was 71% (90/126), with an incidence rate of 5.5 per 1000 patient-day. Higher tacrolimus and prednisolone dosages were associated with CMV infection with an adjusted hazard ratio of 1.2 (95%CI 1.0-1.4, p = .02) and 2.4 (95%CI 1.9-3.4, p < .001), respectively. The consequences of CMV infection did not differ significantly for the low and high CMV VL cut-off groups. CMV infection in LT recipients is common and is associated with higher tacrolimus and corticosteroid dosage. Additionally, using the CMV VL cut-off at 2000 IU/mL to initiate antiviral therapy is practical and effective in preventing CMV disease.
Sections du résumé
BACKGROUND
BACKGROUND
Cytomegalovirus (CMV) infection is the most common infection following pediatric liver transplantation (LT). Preemptive therapy (PET) is an approach to initiate antiviral treatment for asymptomatic early CMV viremia detected by surveillance testing. However, data on CMV infection after PET are scarce, and the optimal cut-off remains controversial. This study aimed to evaluate the incidence, risk factors, and consequences of CMV infection in pediatric LT using 2 different viral load (VL) cut-offs.
METHODS
METHODS
We retrospectively reviewed patients aged 0-18 years who underwent LT at Ramathibodi Hospital between March 2001 and August 2020. Demographic data, CMV infection, CMV treatment, and consequences of CMV infection were collected. CMV viremia was monitored by a quantitative nucleic acid amplification test. Clinical outcomes were compared after starting antiviral therapy at a low (>400 but <2000 IU/mL) and a high VL cut-off (≥2000 IU/mL).
RESULTS
RESULTS
A total of 126 patients were included. CMV infection was 71% (90/126), with an incidence rate of 5.5 per 1000 patient-day. Higher tacrolimus and prednisolone dosages were associated with CMV infection with an adjusted hazard ratio of 1.2 (95%CI 1.0-1.4, p = .02) and 2.4 (95%CI 1.9-3.4, p < .001), respectively. The consequences of CMV infection did not differ significantly for the low and high CMV VL cut-off groups.
CONCLUSION
CONCLUSIONS
CMV infection in LT recipients is common and is associated with higher tacrolimus and corticosteroid dosage. Additionally, using the CMV VL cut-off at 2000 IU/mL to initiate antiviral therapy is practical and effective in preventing CMV disease.
Substances chimiques
Tacrolimus
WM0HAQ4WNM
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14057Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm. 2005;62:S7-13.
Simon DM, Levin S. Infectious complications of solid organ transplantations. Infect Dis Clin N Am. 2001;15:521-549.
George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med. 1997;103:106-113.
Mañez R, Breinig MC, Linden P, et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease. J Infect Dis. 1997;176:1462-1467.
Beam E, Razonable RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment. Curr Infect Dis Rep. 2012;14:633-641.
Marcelin JR, Beam E, Razonable RR. Cytomegalovirus infection in liver transplant recipients: updates on clinical management. World J Gastroenterol. 2014;20:10658-10667.
Freeman RB Jr. The ‘indirect’ effects of cytomegalovirus infection. Am J Transplant. 2009;9:2453-2458.
Kotton CN, Kumar D, Caliendo AM, et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2013;96:333-360.
Singh N, Wannstedt C, Keyes L, Wagener MM, Cacciarelli TV. Who among cytomegalovirus-seropositive liver transplant recipients is at risk for cytomegalovirus infection? Liver Transpl. 2005;11:700-704.
Herman D, Han H. Cytomegalovirus in liver transplant recipients. Curr Opin Organ Transplant. 2017;22:345-350.
Yadav SK, Saigal S, Choudhary NS, Saha S, Kumar N, Soin AS. Cytomegalovirus infection in liver transplant recipients: current approach to diagnosis and management. J Clin Exp Hepatol. 2017;7:144-151.
Levitsky J, Singh N, Wagener MM, Stosor V, Abecassis M, Ison MG. A survey of CMV prevention strategies after liver transplantation. Am J Transplant. 2008;8:158-161.
Biron KK. Antiviral drugs for cytomegalovirus diseases. Antiviral Res 2006;71:154.
Nicastro E, Giovannozzi S, Stroppa P, et al. Effectiveness of preemptive therapy for cytomegalovirus disease in pediatric liver transplantation. Transplantation. 2017;101:804-810.
Annemans L, Moeremans K, Mutimer D, Schneeberger H, Milligan D, Kubin M. Modeling costs and cost-effectiveness of different CMV management strategies in liver transplant recipients as a support for current and future decision making. Value Heal. 2002;5:347-358.
Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34:1094-1097.
Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13512.
Mecadon K, Jandovitz N, Salerno D, et al. Treatment of Epstein-Barr Virus Viremia in pediatric intestinal and liver transplant recipients. Transplantation. 2017;101(6S2):S135.
Comak E, Akman S, Ongut G, et al. Epstein-Barr virus infection in children with renal transplantation: 17 years experience at a single center. Ren Fail. 2014;36(5):760-766.
Kim R, Joung D, Lee S, et al. Cytomegalovirus infection under a hybrid strategy in pediatric liver transplantation: a single-center experience. Pediatr Gastroenterol Hepatol Nutr. 2017;20:178-185.
Saitoh A, Sakamoto S, Fukuda A, et al. A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation. Transplantation. 2011;92:930-935.
Singh N, Winston DJ, Razonable RR, et al. Effect of Preemptive therapy vs antiviral prophylaxis on cytomegalovirus disease in seronegative liver transplant recipients with seropositive donors: a randomized clinical trial. JAMA. 2020;323:1378-1387.
Kawano Y, Mizuta K, Sanada Y, et al. Risk factors of cytomegalovirus infection after pediatric liver transplantation. Transplant Proc. 2014;46:3543-3547.
Siekierka JJ, Hung SH, Poe M, et al. A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature. 1989;341:755-757.
Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin Microbiol Rev. 2009;22:76-98.
Tu W, Chen S, Sharp M, et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol. 2004;172:3260-3267.
Schmidt-Hieber M, Schwarck S, Stroux A, et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol. 2010;91:877-885.
Pastore D, Delia M, Mestice A, et al. Recovery of CMV-specific CD8+ T cells and T regs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2010;17:550-557.
Lacey SF, Diamond DJ, Zaia JA. Assessment of cellular immunity to human cytomegalovirus in recipients of allogeneic stem cell transplants. Biol Blood Marrow Transplant. 2004;10:433-447.
Verma Y, Gupta E, Kumar N, Hasnain N, Bhadoria AS, Pamecha V, Khanna R. Earlier and higher rates of cytomegalovirus infection in pediatric liver transplant recipients as compared to adults: an observational study. J Lab Physicians. 2018;10:221-225.
Simon P, Sasse M, Laudi S, Petroff D, Bartels M, Kaisers UX, Bercker S. Two strategies for prevention of cytomegalovirus infections after liver transplantation. World J Gastroenterol. 2016;22:3412-3417.